



**Aspiro Pharma Limited**  
 H.NO.8-3-166/7/1,3rd floor, Erragadda,  
 Hyderabad 500018, Telangana State, India  
 Tel: +91-40-23704925,Fax:+91-04023704926  
 Web: www.aspiropharma.com  
 CIN No.:U24100TG2014PLC092771

**SAFETY DATA SHEET**

Section 1: Identification	
<b>GHS Product identifier</b>	Succinylcholine Chloride Injection, USP
<b>Trade Name</b>	--
<b>Recommended use</b>	Pharmaceutical product
<b>Manufacturer</b>	<b>Aspiro Pharma Limited,</b> Sy. No. 321, Biotech Park, Phase-III, Karkapatla Village, Markook Mandal, Telangana (S), Siddipet (Dist.)-502281, India.
<b>Distributor</b>	<b>Camber Pharmaceuticals, Inc,</b> Piscatway, NJ 08854
Section 2: Hazard(s) Identification	
<b>GHS - Classification</b>	Acute Oral Toxicity: Category 4
<b>Hazard statement</b>	Warning H302 - Harmful if swallowed
<b>Precautionary Statements:</b>	P264 - Wash hands thoroughly after handling P270 - Do not eat, drink or smoke when using this product P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell P501 - Dispose of contents/container in accordance with all local and national regulations
Section 3: Composition/Information on Ingredients	
Ingredients	CAS
Succinylcholine Chloride	71-27-2
Sodium hydroxide	1310-73-2
Hydrochloric acid	7647-01-0
Sodium chloride	7647-14-5
Propylparaben	94-13-3
Water for Injection	7732-18-5
Methylparaben	99-76-3
Section 4: First-Aid Measures	
<b>Eye Contact</b>	Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.



**Aspiro Pharma Limited**

H.NO.8-3-166/7/1,3rd floor, Erragadda,  
Hyderabad 500018, Telangana State, India  
Tel: +91-40-23704925,Fax:+91-04023704926  
Web: www.aspiropharma.com  
**CIN No.:U24100TG2014PLC092771**

<b>Skin Contact</b>	Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
<b>Inhalation</b>	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
<b>Section 5: Fire-Fighting Measures</b>	
<b>Suitable Extinguishing Media</b>	As for primary cause of fire.
<b>Unsuitable Extinguishing Media</b>	No data Available
<b>Specific hazards arising from During fire, gases hazardous to health may be formed. the chemical</b>	Formation of toxic gases is possible during heating or fire. May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride, and other chlorine-containing compounds.
<b>Special protective equipment and precautions for firefighters</b>	No data Available
<b>special firefighting procedures</b>	During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
<b>Specific methods</b>	No data Available
<b>Section 6: Accidental Release Measures</b>	
<b>Personal precautions, protective equipment and emergency procedures</b>	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
<b>Environmental precautions</b>	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
<b>Methods and materials for containment and cleaning up</b>	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.



**Aspiro Pharma Limited**

H.NO.8-3-166/7/1,3rd floor, Erragadda,  
 Hyderabad 500018, Telangana State, India  
 Tel: +91-40-23704925,Fax:+91-04023704926  
 Web: www.aspiropharma.com  
**CIN No.:U24100TG2014PLC092771**

<b>Additional Consideration for Large Spills</b>	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
<b>Section 7: Handling and Storage</b>	
<b>Handling</b>	Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
<b>Conditions for safe storage, including any incompatibilities</b>	<b>Store in refrigerator 2° to 8°C (36° to 46°F).</b>
<b>Section 8: Exposure Controls/Personal Protection</b>	
Appropriate engineering Control	Airborne exposure should be controlled primarily by engineering controls such as general dilution Ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing Dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Local exhaust ventilation such as a laboratory fume hood or other vented enclosure is Recommended, particularly for grinding, crushing, weighing, or other dust-generating procedures.
<b>Individual protection measures, such as personal protective equipment</b>	



**Aspiro Pharma Limited**

H.NO.8-3-166/7/1,3rd floor, Erragadda,  
Hyderabad 500018, Telangana State, India  
Tel: +91-40-23704925,Fax:+91-04023704926  
Web: www.aspiropharma.com  
CIN No.:U24100TG2014PLC092771

Eye/face protection	Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.
Skin protection Hand protection	Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.
Respiratory protection	Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection.

**Section 9: Physical and Chemical Properties**

<b>Section 9, Physical and chemical properties</b>	
Physical State	Liquid
Colour	A clear, colorless solution
Odor	No data available
Description	<p><b>Succinylcholine Chloride Injection USP 200 mg/10 mL (20 mg/mL)</b></p> <p>Succinylcholine Chloride Injection, USP is supplied as a clear, colorless solution in 10 mL multiple-dose vials. Each mL contains succinylcholine chloride, USP 20 mg.</p> <p>10 mL Multiple-dose Flip-top Vial (NDC 31722-981-10)</p> <p>25 Vials in a Carton (NDC 31722-981-31)</p>

**Section 10: Stability and Reactivity**

<b>Section 10, Stability and reactivity</b>	
Reactivity	No data available
Chemical stability	Stable under normal conditions of use.



**Aspiro Pharma Limited**

H.NO.8-3-166/7/1,3rd floor, Erragadda,  
Hyderabad 500018, Telangana State, India  
Tel: +91-40-23704925, Fax: +91-04023704926  
Web: www.aspiropharma.com  
CIN No.:U24100TG2014PLC092771

<b>Possibility of Hazardous Reactions</b>	
<b>Oxidizing Properties</b>	None
<b>Conditions to avoid</b>	None known
<b>Incompatible materials</b>	None known
<b>Hazardous decomposition Products</b>	Thermal decomposition products may include carbon monoxide, carbon dioxide, oxides of nitrogen and hydrogen chloride
<b>Section 11: Toxicological Information</b>	
<b>Information on Toxicological Effects</b>	
<b>General Information</b>	The information included in this section describes the potential hazards of the individual ingredients.
<b>Known Clinical Effects</b>	The most common adverse effects seen during clinical use of this drug include increase in blood pressure (hypertension), decrease in blood pressure (hypotension), respiratory arrest, troubled breathing, irregular heartbeat (cardiac arrhythmia), slow heart rate (bradycardia), increased heart rate (tachycardia),
<b><u>Acute Toxicity: (Species, Route, End Point, Dose)</u></b>	
<b>SODIUM CHLORIDE</b> Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m3 Rat Oral LD 50 3g/kg Mouse Oral LD 50 4g/kg Rabbit Dermal LD 50 > 10g/kg	
<b>Propylparaben</b> Mouse Oral LD 50 6332 mg/kg Mouse Sub-tenon injection (eye) LD 50 200 mg/kg	
<b>HYDROCHLORIC ACID</b> Rat Oral LD 50 238-277 mg/kg	
<b>Succinylcholine Chloride</b> Mouse Oral LD50 125 mg/kg Mouse IV LD50 0.43mg/kg Rabbit IV LD50 0.24mg/kg	
<b><u>Irritation / Sensitization: (Study Type, Species, Severity)</u></b>	
<b>SODIUM CHLORIDE</b> Skin Irritation Rabbit Mild; Eye Irritation Rabbit Mild	
<b>Propylparaben</b> 3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system 4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system	
<b><u>Genetic Toxicity: (Study Type, Cell Type/Organism, Result)</u></b>	
<b>HYDROCHLORIC ACID</b> Bacterial Mutagenicity (Ames) <i>Salmonella</i> Negative; <i>In Vivo</i> Micronucleus Rat Negative	
<b><u>Carcinogen Status:</u></b>	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA
<b>HYDROCHLORIC ACID IARC:</b>	Group 3 (Not Classifiable)



**Aspiro Pharma Limited**

H.NO.8-3-166/7/1,3rd floor, Erragadda,  
Hyderabad 500018, Telangana State, India  
Tel: +91-40-23704925,Fax:+91-04023704926  
Web: www.aspiropharma.com  
CIN No.:U24100TG2014PLC092771

**Section 12: Ecological Information**

<b>Environmental Overview:</b>	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
<b>Toxicity:</b>	No data available
<b>Persistence and Degradability:</b>	No data available
<b>Bio-accumulative Potential:</b>	No data available
<b>Mobility in Soil:</b>	No data available

**Section 13: Disposal Considerations**

<b>Waste treatment methods</b>	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and waste water.
--------------------------------	--

**Section 14: Transport Information**

The following refers to all modes of transportation unless specified below.  
Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

**Section 15: Regulatory Information**

**Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture**

<b>Succinylcholine Chloride</b> CERCLA/SARA 313 Emission reporting California Proposition 65 Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present 200-747-4
<b>SODIUM CHLORIDE</b> CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 231-598-3
<b>Propylparaben</b> CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 202-307-7
<b>Water for Injection</b> CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	Not Listed Not Listed Present



**Aspiro Pharma Limited**  
 H.NO.8-3-166/7/1,3rd floor, Erragadda,  
 Hyderabad 500018, Telangana State, India  
 Tel: +91-40-23704925,Fax:+91-04023704926  
 Web: www.aspiropharma.com  
**CIN No.:U24100TG2014PLC092771**

REACH - Annex IV - Exemptions from the obligations of Register:  EU EINECS/ELINCS List	Present Present  231-791-2
<b>SODIUM HYDROXIDE</b> <b>CERCLA/SARA 313 Emission reporting</b> <b>CERCLA/SARA Hazardous Substances and their Reportable Quantities:</b> <b>California Proposition 65</b> <b>Inventory - United States TSCA - Sect. 8(b)</b> <b>Australia (AICS):</b> <b>Standard for the Uniform Scheduling for Drugs and Poisons:</b> <b>EU EINECS/ELINCS List</b>	Not Listed 1000 lb 454 kg Not Listed Present Present Schedule 5 Schedule 6 215-185-5
<b>Methylparaben</b> <b>CERCLA/SARA 313 Emission reporting</b> <b>California Proposition 65</b> <b>Inventory - United States TSCA - Sect. 8(b)</b> <b>Australia (AICS):</b> <b>EU EINECS/ELINCS List</b>	Not Listed Not Listed Present Present 202-785-7
<b>HYDROCHLORIC ACID</b> <b>CERCLA/SARA 313 Emission reporting</b> <b>CERCLA/SARA Hazardous Substances and their Reportable Quantities:</b> <b>CERCLA/SARA - Section 302 Extremely Hazardous TPQs</b> <b>CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs</b> <b>California Proposition 65</b> <b>Inventory - United States TSCA - Sect. 8(b)</b> <b>Australia (AICS):</b>	1.0 % 5000 lb 2270 kg 500 lb  5000 lb  Not Listed Present Present
<b>Standard for the Uniform Scheduling for Drugs and Poisons:</b> <b>EU EINECS/ELINCS List</b>	Schedule 5 Schedule 6 231-595-7

### Section 16: Other Information

**Text of CLP/GHS Classification abbreviations mentioned in Section 3**

**Issue Date : 14-05-2020**

**Version : 00**

**Further information**

**Revision date: New issue**

**Revision note: New issue**

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Aspiro Pharma Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Aspiro Pharma Limited reserves the right to revise this SDS.